Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Oct 15, 2016 6:08pm

218 Views

Post# 25347599

RE:RE:Post by F6 on Investor Village Oct 5th 2016

GV where I am interested is in Pfizer getting XTANDI® (enzalutamide) in this deal and the zen3694 mCRPC trial started by Zenith and the possible synergy between enzalutamide and zen3694. We probably won't know anything for months but if positive it could be good for Zenith.

I do believe something is up and I believe this because of the delayed AGMs.

Other than that I know nothing.
GLTA
Toinv

Bullboard Posts

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle